anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention belongs to the technical field of biology, and provides an enzymolysis-resistant antibacterial peptide II4II, and a preparation method and application thereof. The amino acid sequence of the antibacterial peptide II4II is shown in SEQ ID No. 1. The preparation method comprises the following steps: based on the specific enzyme cutting sites of trypsin, chymotrypsin and pepsin and the basic characteristics of the antibacterial peptide, amino acids in the sequence are reasonably arranged, and Ile is selected as hydrophobic amino acid to obtain the antibacterial peptide II4 II. The application of the antibacterial peptide II4II in preparing medicines for treating gastrointestinal tract infection diseases caused by gram-negative bacteria or/and gram-positive bacteria. The antibacterial peptide II4II has a strong inhibiting effect on various bacteria, is low in hemolytic activity, has a treatment index of 80.63, has strong enzymolysis resistance, keeps the antibacterial activity unchanged after treatment of trypsin, chymotrypsin or pepsin, and has application potential of becoming an antibiotic substitute.
Data on CRC patients with synchronous liver metastasis (LM) were derived from the US Surveillance, Epidemiology, and End Results (SEER) and a Chinese registry (from two Chinese tertiary centers: The Second Affiliated Hospital of Harbin Medical University and National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences \& Peking Union Medical College) between January 2010 and December 2017. Individual level data on patients with incident CRC were consecutively collected in both registries. The primary tumor site was divided into three subsites according to International Classification of Diseases for Oncology (ICD-O-3) topography codes: proximal colon (C18.0, C18.1, C18.2, C18.3 and C18.4), distal colon (C18.5, C18.6, C18.7) and rectum (C19.9 and C20.9). The synchronous LM were identified by imaging or histopathological examinations. Synchronous LM refers to liver lesions found within 6 months after the diagnosis of primary CRC. Patients were excluded if they did not undergo surgery for CRC, did not have data on number of LNs retrieved and their survival status was unknown.
The patients were told how to prepare and apply the temperature and salt ratio of the water to be used in the hand and foot bath (280 grams of rock salt to 8 liters of water) with a demonstration method with video training. video tutorial tablet It was done in a quiet environment in the hospital, in a room with the patient and the researcher. The temperature of the water and the duration of application were determined based on research that previously examined the effectiveness of warm water and warm salt water baths in various patient groups. Bath hours were determined to be between 21:00 and 22:00 in order to prevent the patients from doing any activity after this application and to provide relaxation and rest after the bath. Starting 1 day after the training, each patient is at home for six weeks from 21:00 to He applied a warm salt water bath at 41°C for 20 minutes to his hands and feet three times a week between 21:00-22:00.
Patients with cirrhosis commonly have deranged coagulation parameters, in particular thrombocytopenia and/or an increased INR. However, these laboratory findings do not necessarily correlate with an increased tendency of bleeding. In fact, the reduced synthesis of both pro- and anticoagulant factors often equates to a new equilibrium in the coagulation system. Nevertheless, out of fear of bleeding, liver cirrhosis patients with deviated laboratory coagulation parameters are often aggressively treated with coagulation products (such as platelet concentrates and prothrombin complex concentrate (PCC)) before minor interventions and punctures. Since these products can also have procoagulant side effects, we will investigate whether patients with liver cirrhosis without a history of bleeding or clinical bleeding signs benefit from a restrictive substitution regime. The study will be carried out monocentrically at the General Hospital of Vienna, and will include 400 patients divided into two groups (liberal vs. restrictive substitution of thrombocytes and/or PCC) over an est. period of 4 years.
Participants in the active control group will download use the Healthy365 app, a mobile health application managed by the Singapore government's Health Promotion Board. The Healthy365 app offers a variety of useful general health-related content which are not specific to skin disease. These include personalized health tracking, participation in fitness challenges, access to nutritional guidance, and personalized lifestyle recommendations.
Individuals that have not been previously diagnosed with Metabolic Syndromes including Type 2 Diabetes, obesity, or increased levels of blood sugar. HbA1C values below 5.7%.
Biollogically stable lyophilised gamma interferon (GIF) formulation contains a compatible buffer which gives a pH of 4.0 to 6.0 when the formulation is dissolved in water to give a GIF concentration of 0.001 to 10 mg, pref. 0.05 mg per ml. Additionally the formulation may contain a solubilizer, an antioxidant, a bulking agent or a chelating agent. Buffer is pref. based on citric acid or dibasic sodium phosphate. The reconstituted formulation remains stable form at least 24 hr. at room temp.
Subjects receive pemetrexed 500 mg/m\^2 and carboplatin Area Under the Curve (AUC) 5, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m\^2 every three weeks (Q3W) maintenance for the remainder of the study or until documented PD. If PD occurs, Subjects may be able to receive SHR-1210 Q3W for the remainder of the study or until documented PD.
The study drug, EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule, is a fixed-dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine. It is manufactured by Exeltis İlaç San. ve Tic. A.Ş., Turkey. It is an antibacterial and antifungal medication that will be used in the treatment of common vaginitis (e.g. bacterial vaginosis, candidal vulvovaginitis). Its efficacy and safety were previously evaluated in a Phase III clinical trial. In this single-center, single-arm, single-dose, bioavailability study, pharmacokinetic parameters for each active ingredient will be evaluated in 18 healthy female subjects following intravaginal administration of this fixed-dose combination.
No intervention will be made to the control group. This group will be given a first test using the scales specified in the data collection, and a final test will be given 30 days later using the same scales.
<P>PROBLEM TO BE SOLVED: To provide a portable biological information monitor device capable of always monitoring biological information without requiring replacement of devices, and an information management device for processing and displaying the information prepared by the monitor device.  <P>SOLUTION: The biological information monitor device detects pulse wave detection signals obtained by emitting green LEDs and body motion detection signals obtained by emitting infrared LEDs as biological information. When the set mode of preparation is a waking/normal mode, the body motion and pulse wave are calculated by analyzing the biological information as waking evaluation indexes for evaluating a subject in the waking state (S320). When the mode of preparation is a waking/regular kinetic motion mode, the body movement, pulse wave and pitch (S380) are calculated as kinetic motion evaluation indexes for evaluating the state of the subject in the regular moving state. When the mode of preparation is a sleeping mode, the body motion, pulse wave and autonomic nerve function (S420) are calculated as the sleeping evaluation indexes for evaluating the state of the subject in the sleeping state. Accordingly, all the necessary indexes can be prepared by one monitor device without depending on the behavior of the subject.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Participants ≥3 months to \<2 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1. Participants in this cohort enrolled after interim analysis for Cohort 3 received TOL/TAZ 30/15 mg/kg.
FIELD: biotechnology, medicine, pharmacy, veterinary science. SUBSTANCE: invention relates to medicinal forms of medicinal immunobiological preparations with bacteriophages as an active component. Gel medicinal form with bacteriophages has one or some species of concentrated bacteriophages as active components that are distributed in polymer or polymers (water-swelling hydrophilic high-molecular compound), preserving agent, plant extracts, essential oils. Invention provides rapid absorption, gel does not impair skin cells respiration and provides uniform distribution of phage particles. EFFECT: improved properties, enhanced effectiveness of treatment. 11 cl
The method for assessing the adhesion of bacteria to dentistry materials used for denture manufacture comprises in incubation of the disks prepared from the materials under study in the suspension of test-cultures of bacteria followed by placing the disks to the saline solution and analyzing the imprints of the materials on the surface of the solid nutrient media for bacterial culture. Upon incubation, the number of the isolated bacterial colonies is counted. For transferring the adhered bacteria to the sterile saline solution, the tubes with the disks are shaken for 5, 10, and 15 minutes. The number of the bacteria transferred to the saline solution is measured upon seeding the samples in the nutrient media. Finally, the complex assessment of the adhesive properties of the materials under study is performed. Based on the results of the assays, the dentistry materials used for denture manufacture are categorized as follows: the materials with low adhesion of bacteria, the materials with moderate adhesion of bacteria, and the materials with high adhesion of bacteria.
This is a phase I dose escalating study designed to identify tolerable, clinically active doses of cisplatin delivered as intraoperative intraperitoneal hyperthermic chemoperfusion (HIPEC) in patients with platinum-sensitive recurrent ovarian cancer. After surgical cytoreduction, a single dose of cisplatin will be administered in 3 liters normal saline via intraperitoneal HIPEC with closed-abdomen technique for 90 minutes in the hyperthermic phase (41-43 degrees C). After completion of perfusion, the perfusate will be drained, the abdomen opened and the abdomen and pelvis irrigated with 2-3 liters normal saline to wash away any residual chemotherapeutic agent. Fascia and skin will then be closed in a standard fashion. Cisplatin infusion will be discontinued for unacceptable toxicity. The primary objective is to determine the maximum tolerated dose (MTD) of cisplatin administered as HIPEC. Secondary objectives are to determine pharmacokinetics and pharmacodynamics as well as the effect of cisplatin as HIPEC on the ability to subsequently administer 6 cycles of standard platinum-based systemic chemotherapy.
In this group patients will performed functional task training program was performed including non-walking (i-iii) and walking activities: (i) standing from a seated position; (ii) reaching for an object overhead, which required ankle plantar flexion from the standing position, and returning to the initial position with the heel leaning on the floor; (iii) stepping on and off a bench; (iv) walking up and down stairs; and (v) walking on flat surfaces and ramps. for 8 weeks, 50 minutes per day, 3 times per week. The individual session lasted approximately 10 minutes including the rest intervals.
<P>PROBLEM TO BE SOLVED: To provide a medicine containing at least one double-stranded oligoribonucleotide (dsRNA) designed to inhibit the expression of a target gene.  <P>SOLUTION: One strand of the dsRNA is at least in part complementary to the target gene. The target gene can be selected from the following group: a cancer gene, a cytokine gene, an Id protein gene, a developmental gene, and a prion gene. The target gene can be expressed in a pathogenic organism (especially, Plasmodium). The target gene can also preferably be a part of a virus or viroid which is pathogenic to human.  <P>COPYRIGHT: (C)2009,JPO&INPIT
At the PSIB group, the block will be performed by ultrasound guidance after completion of surgery. PSIB Blocks will be performed under ultrasonography guidance using a linear 6 to 13 megahertz ultrasound probe by the anesthesist.In PSIB group patients will receive 40 ml %0.375 bupivacaine divided into 4 equal doses between psoas major muscle and external intercostal muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space bilaterally.
In the present invention there are disclosed 9-[(substituted glycyl)amido)]-6-demethyl-6-deoxytetracykline compounds of the general formula I, in which R represents hydrogen; Re1 represents hydrogen or alkyl containing 1 to 3 carbon atoms; W represents an amino group, being optionally substituted with one group being selected from a group comprising alkyl having 1 to 8 carbon atoms, cycloalkylmethyl containing 3 to 6 carbon atoms in the cycloalkyl moiety, phenylmethyl, pyridylmethyl and thienylmethyl or with two alkyl groups having 1 to 3 carbon atoms; N-pyrrolidinyl or N-piperidyl, whereby each of the later groups can be optionally substituted with one methyl; and their pharmacologically acceptable salts with organic or inorganic acids. The compounds of the general formula III, in which Y represents bromine, chlorine, iodine or fluorine and R and Re1 are as specified above and their salts with organic and inorganic acids as intermediates for preparing the compounds of the general formula I. A process for preparing the compounds of the general formula I by reacting the compound of the general formula III with nucleophilic compound of the general formula WH, wherein W is as specified above in a polar aprotic solvent and in inert atmosphere. A process for preparing the compounds of the general formula I by reacting the compound of the general formula 1, wherein R represents hydrogen with a chloride of the compound of the general formula  (R,Re1,W)C-C(=O)X, in which R and Re1 and W are as specified above and X represents bromine, chlorine, iodine or fluorine, in an inert solvent and in polar aprotic solvent in the presence of a base. In the present invention there are also claimed pharmaceutical and veterinary preparations based on the compounds of the general formula I. The compounds of the general formula I are antibacterial agents.
Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable clinical efficacy, but challenges related to relapse and CAR-T cell exhaustion persist. One contributing factor to this exhaustion is CAR tonic signaling, where CAR-T cells self-activate without antigen stimulation, leading to reduced persistence and impaired antitumor activity. To address this issue, we conducted a preclinical study evaluating tonic signaling using nanobody-derived CAR-T cells. Our investigation revealed that specific characteristics of the complementary determining regions (CDRs), including low solubility, polarity, positive charge, energy, and area of ionic and positive CDR patches of amino acids, were associated with low antigen-independent tonic signaling. Significantly, we observed that stronger tonic signaling directly impacted CAR-T cell proliferation in vitro, consequently leading to CAR-T cell exhaustion and diminished persistence and effectiveness in vivo. Our findings provide compelling preclinical evidence and lay the foundation for the clinical assessment of CAR-T cells with distinct tonic signaling patterns. Understanding the role of CDRs in modulating tonic signaling holds promise for advancing the development of more efficient and durable CAR-T cell therapies, thereby enhancing the treatment of cancer and addressing the challenges of relapse in CAR-T cell therapy.
This invention relates to certain N-heteroaryl compounds that are generally useful as medicaments, more specifically as medicaments for animals. The medicament can preferably be used for the treatment of helminth infections and the treatment of parasitosis, such as caused by helminth infections. This invention also relates to uses of the compounds to make medicaments and treatments comprising the administration of the compounds to animals in need of the treatments. This invention also relates to N-heteroaryl compounds and the preparation of said compounds. Moreover this invention relates to pharmaceutical compositions and kits comprising the compounds. (see formula I)
Traditional cardiomyopathy paradigms segregate inflammatory etiologies from those caused by genetic variants. An identified or presumed trigger is implicated in acute myocarditis or chronic inflammatory cardiomyopathy but growing evidence suggests a significant proportion of patients have an underlying cardiomyopathy-associated genetic variant often even when a clear inflammatory trigger is identified. Recognizing a possible genetic contribution to inflammatory cardiomyopathy may have major downstream implications for both the patient and family. The presenting features of myocarditis (i.e. chest pain, arrhythmia, and/or heart failure) may provide insight into diagnostic considerations. One example is isolated cardiac sarcoidosis, a distinct inflammatory cardiomyopathy that carries diagnostic challenges and clinical overlap; genetic testing has increasingly reclassified cases of isolated cardiac sarcoidosis as genetic cardiomyopathy, notably altering management. On the other side, inflammatory presentations of genetic cardiomyopathies are likewise underappreciated and a growing area of investigation. Inflammation plays an important role in the pathogenesis of several familial cardiomyopathies, especially arrhythmogenic phenotypes. Given these clinical scenarios, and the implications on clinical decision making such as initiation of immunosuppression, sudden cardiac death prevention, and family screening, it is important to recognize when genetics may be playing a role.
Fluticasone propionate cream USP, 0.05% contains fluticasone propionate USP [(6α,11β,16α,17α)-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic acid S-fluoromethyl ester], a synthetic fluorinated corticosteroid, for topical dermatologic use. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. 

Chemically, fluticasone propionate is C25H31F3O5S. It has the following structural formula: 

Fluticasone propionate USP has a molecular weight of 500.6. It is a white to off-white powder and is insoluble in water. 

Each gram of fluticasone propionate cream USP, 0.05% contains fluticasone propionate USP 0.5 mg in a base of propylene glycol, mineral oil, cetostearyl alcohol, Ceteth-20, isopropyl myristate, dibasic sodium phosphate, citric acid, purified water and imidurea as preservative.
Promethazine HCl tablets may cause marked drowsiness or impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as driving a vehicle or operating machinery. The use of alcohol or other central-nervous-system depressants such as sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers, may enhance impairment (see WARNINGS: CNS Depression and PRECAUTIONS: Drug Interactions). Pediatric patients should be supervised to avoid potential harm in bike riding or in other hazardous activities. 

Patients should be advised to report any involuntary muscle movements. 

Avoid prolonged exposure to the sun. 

A patient information leaflet is included and summarizes important information about promethazine.
PURPOSE: A composition containing Galla Rhois ethanol extract is provided to suppress lung cancer growth and to prevent and treat lung cancer. CONSTITUTION: A composition for preventing and treating lung cancer contains Galla Rhois ethanol extract as an active ingredient, prepared by extracting Galla Rhois at 50 Deg. C. for 24 hours and decompressing at 45 Deg. C. The composition additionally contains pharmaceutically acceptable carriers or diluents. A functional food for preventing lung cancer contains the ethanol extact as an active ingredient, containing sitologically acceptable food additives. [Reference numerals] (AA) Galla Rhois
The invention discloses a Chinese medicinal fumigant for treatment of postoperative lumbar spinal stenosis. According to traditional Chinese medicine, kidney deficiency is the root cause, and wind cold, dampness and heat, phlegm retention, Qi-stagnation and blood stasis, phlegm, and sudden muscle strain or contusion are syndromes. The kidney governs bone marrow generation, and the liver nourishes tendons and stores blood. Liver-kidney deficiency and malnutrition of muscles and bones can cause lumbar and leg pain. In addition, phlegm dampness and stagnation, and collateral blockage are also important factors for lumbar spinal stenosis. Thus, treatment can be mainly based on promoting blood circulation to remove blood stasis, alleviating paralysis and moistening meridian tendon, nourishing liver and easing pain. According to the invention, valerian root, Vaccinium bracteatum Thunb, Osmanthus heterophyllus, root and leaf of Vaccinium fragile Franch., Campylotropis macrocarpa, rhizoma arisaematis, phoenix tree leaf, Corydalis esquirolii Levl., and Habenaria delavayi Finet are prepared into the fumigant by a drug preparation room of the hospital. Clinical tests prove that the Chinese medicinal fumigant has a total effective rate up to 90.0% that is significantly better than a control group, and has significant effect.
The study will use an Enriched Enrollment Randomized Withdrawal (EERW) design consisting of a 2-week open-label enrichment phase, during which subjects will receive etoricoxib. Patients who experience at least a 30% reduction in pain intensity will be randomized to either continued treatment with etoricoxib 90 mg qd or matching placebo (at a 1:1 ratio) for 4 weeks.
This is a phase 2 study in older adults with at least mild progressive behavioral symptoms, subjective sleep maintenance problems, and at least mild progressive cognitive deficit. The study is a randomized, double-blind, placebo-controlled, three-way crossover design, in which participants will receive oral placebo, low dose MMFS, and high dose MMFS twice daily for 6 weeks. Over three study periods (2 weeks each), subjects will receive two different dosages of MMFS (low dose: \~22.5 mg/kg LBM/day and high dose: \~35 mg/kg LBM/day) and placebo. After periods 1 and 2 there will be a one week washout period in which the subject will not take any study tablets. Randomized patients and their informants (required) will complete 5 assessments total: at baseline in the clinic (visit 1; prior to taking any study tablets), and 4 times at home via online assessments (at the beginning of period 1 and at the end of periods 1, 2, and 3. The effectiveness of different MMFS dosages on cognition, mood, and sleep quality will be assessed using a Neuropsychological Test Battery, Profile of Mood States-Brief Form, daily sleep diaries, and Insomnia Severity Index. The safety profile of different MMFS dosages will be determined by monitoring the AE/SAE and subjective remarks during the study period. A range of safety and tolerability assessments will also be performed (including vital signs and laboratory tests).